NCT06179511CompletedPhase 1
A trial to learn if AZD9829 is safe and works alone and in combination with other treatments for participants with certain blood cancers.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 5 Mar 2026
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (actual)
- First submitted
- 12 Jan 2024
- Start date
- 9 Oct 2024
- Lead sponsor
- Astrazeneca AB
- NCT number
- NCT06179511
- EU CT number
- 2023-506997-11-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 14
- 4 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Goethe University Frankfurt Coordinator of this site? Confirm its status | Frankfurt Am Main | Germany | Completed |
| Hospital Universitari Vall d'Hebron Coordinator of this site? Confirm its status | Barcelona | Spain | Completed |
| Hospital Universitario De Salamanca Coordinator of this site? Confirm its status | Salamanca | Spain | Completed |
| Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico Coordinator of this site? Confirm its status | Bologna | Italy | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.